Publications

(2021). Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals of the rheumatic diseases.
(2021). Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study. British journal of clinical pharmacology.
(2021). Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact. Value in Health.
(2021). Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. Eurosurveillance.
(2021). Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. The Lancet Rheumatology.
(2021). Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study. Journal of hematology & oncology.
(2021). Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England. bmj.
(2020). Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. The Lancet Respiratory Medicine.
(2019). Whole-colon investigation vs. flexible sigmoidoscopy for suspected colorectal cancer based on presenting symptoms and signs: a multicentre cohort study. British journal of cancer.
(2019). Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013--2017. BMJ open.